Supernus Pharmaceuticals SUPN Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$29.02M+24.7% | -$38.55M-102% | -$19.12M-130% | $64.5M+4.2% | $61.91M-16.2% | ||
| $97.31M+6.3% | $91.56M+7.2% | $85.39M+5.8% | $80.69M+0.8% | $80.05M-0.5% | ||
| $33.46M+1.2% | $33.05M+6.5% | $31.03M+0.5% | $30.88M+3.2% | $29.93M+7.8% | ||
| —— | —— | —— | $187.06M+14.0% | $164.15M-4.5% | ||
| $1.01M-24.4% | $1.34M+19.0% | $1.12M-5.9% | $1.2M+48.6% | $804K+10.9% | ||
| —— | —— | —— | —— | -$100.93M+46.8% | ||
| $39.64M+334% | $9.13M+40.6% | $6.49M+156% | -$11.5M-6.7% | -$10.78M-188% | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Supernus Pharmaceuticals's cash flow data come from?
- Every line is extracted from Supernus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.